<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03314493</url>
  </required_header>
  <id_info>
    <org_study_id>U1111-1203-1767</org_study_id>
    <nct_id>NCT03314493</nct_id>
  </id_info>
  <brief_title>Prevention of the Progression of Coronary Calcification With Use of Spironolactone in Peritoneal Dialysis Patients</brief_title>
  <official_title>Effect of Spironolactone on the Progression of Coronary Calcification in Peritoneal Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Professor Fernando Figueira Integral Medicine Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Professor Fernando Figueira Integral Medicine Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vascular calcification is a frequent complication in dialysis patients and is strongly
      associated with mortality. Its pathogenesis is complex and involves a series of markers that
      act on the vascular microenvironment. There is evidence that aldosterone is one of the
      biomarkers and may have a role in osteoinductive pathways.The aim of this study was to
      evaluate the effect of spironolactone, an inhibitor of mineralocorticoid receptor, in the
      progression of coronary calcification in patients undergoing peritoneal dialysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 7, 2014</start_date>
  <completion_date type="Actual">November 10, 2016</completion_date>
  <primary_completion_date type="Actual">November 10, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative progression of the coronary calcium score</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage change in coronary calcium score from baseline to end of study. Coronary calcium score detected using multi-detector computed tomography and expressed in Agatston units.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute progression of the coronary calcium score</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the absolute progression of the coronary calcium score, defined as the difference between the final score and the baseline score. Coronary calcium score detected using multi-detector computed tomography and expressed in Agatston units.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects of spironolactone use</measure>
    <time_frame>12 months</time_frame>
    <description>During follow-up, all patients were assessed monthly to evaluate the frequency of hyperpotassemia (serum potassium &gt; 6mEq/L), hypotension (systolic blood pressure &lt; 100 mmHg) and/or diastolic blood pressure &lt; 60 mmHg) and gynecomastia defined as breast augmentation, painful or not.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year change in laboratory parameters of mineral metabolism</measure>
    <time_frame>12 months</time_frame>
    <description>Assess changes in serum levels of total calcium, phosphorus, alkaline phosphatase, 25(OH) vitamina D and intact parathyroid hormone, through periodic blood dosages of these parameters, during follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for spironolactone dose reduction</measure>
    <time_frame>12 months</time_frame>
    <description>In the presence of adverse effects, the dose of spironolactone was reduced from 25 to 12,5 mg per day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Causes of discontinuation of the study</measure>
    <time_frame>12 months</time_frame>
    <description>Severe hyperpotassemia defined as serum potassium&gt;7mEq/L; lack of improvement in the adverse effects of spironolactone with a dose reduction of 12,5 mg/day, ie, persistence of breasts enlargement, hypotension and hyperpotassemia (serum potassium &lt; 6mEq/L); discontinuation of peritoneal dialysis due to renal transplantation or the need for hemodialysis transfer; withdrawal of consent at any time; and death were considered as causes for discontinuation of the study. For the evaluation of this outcome, the patients were submitted to medical visit and biochemical measures monthly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year change in laboratory parameters related to inflammation.</measure>
    <time_frame>12 months</time_frame>
    <description>Assess changes on serum levels of c-reactive protein, albumin and fetuin-A, through periodic blood dosages of these parameters, during follow-up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Coronary Artery Calcification</condition>
  <condition>Vascular Calcification</condition>
  <arm_group>
    <arm_group_label>Spironolactone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spironolactone oral tablet 25mg/day, for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No spironolactone use</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone 25Mg Tablet</intervention_name>
    <description>Patients with coronary calcium score &gt; 30 were treated with spironolactone for 12 months</description>
    <arm_group_label>Spironolactone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Coronary calcium score &gt; 30 Agatston unit

          -  Peritoneal dialysis for at least 6 months

        Exclusion Criteria:

          -  Use of spironolactone in the last 3 months

          -  Mean serum potassium &gt; 6 mEq/L in the last 3 months

          -  Cardiac revascularization surgeries

          -  Arrhythmias

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Paula S Gueiros, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Medicina Integral Prof. Fernando Figueira</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alex SR Souza, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Medicina Integral Prof. Fernando Figueira</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aluizio B Carvalho, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universidade Federal de São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José E Gueiros, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto de Medicina Integral Prof. Fernando Figueira</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leuridan T Cavalcante, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto de Medicina Integral Prof. Fernando Figueira</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dulce E Casarini, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidade Federal de São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marina M Cadena</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto de Medicina Integral Prof. Fernando Figueira</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karina T Nobrega, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto de Medicina Integral Prof. Fernando Figueira</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eveline B Calado, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto de Medicina Integral Prof. Fernando Figueira</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de Medicina Integral Prof. Fernando Figueira</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50070-550</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Fischer SS, Kempe DS, Leibrock CB, Rexhepaj R, Siraskar B, Boini KM, Ackermann TF, Föller M, Hocher B, Rosenblatt KP, Kuro-O M, Lang F. Hyperaldosteronism in Klotho-deficient mice. Am J Physiol Renal Physiol. 2010 Nov;299(5):F1171-7. doi: 10.1152/ajprenal.00233.2010. Epub 2010 Aug 18.</citation>
    <PMID>20719979</PMID>
  </reference>
  <reference>
    <citation>Voelkl J, Alesutan I, Leibrock CB, Quintanilla-Martinez L, Kuhn V, Feger M, Mia S, Ahmed MS, Rosenblatt KP, Kuro-O M, Lang F. Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice. J Clin Invest. 2013 Feb;123(2):812-22. doi: 10.1172/JCI64093. Epub 2013 Jan 9.</citation>
    <PMID>23298834</PMID>
  </reference>
  <reference>
    <citation>Tatsumoto N, Yamada S, Tokumoto M, Eriguchi M, Noguchi H, Torisu K, Tsuruya K, Kitazono T. Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification. Am J Physiol Renal Physiol. 2015 Dec 1;309(11):F967-79. doi: 10.1152/ajprenal.00669.2014. Epub 2015 Sep 2.</citation>
    <PMID>26336165</PMID>
  </reference>
  <results_reference>
    <citation>Nitta K, Akiba T, Nihei H. Aldosterone blockade and vascular calcification in hemodialysis patients. Am J Med. 2003 Aug 15;115(3):250.</citation>
    <PMID>12935835</PMID>
  </results_reference>
  <results_reference>
    <citation>Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, Yakushigawa T, Sugiyama H, Shimada Y, Nojima Y, Shio N. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol. 2014 Feb 18;63(6):528-36. doi: 10.1016/j.jacc.2013.09.056. Epub 2013 Oct 30.</citation>
    <PMID>24184249</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2017</study_first_submitted>
  <study_first_submitted_qc>October 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2017</study_first_posted>
  <last_update_submitted>October 15, 2017</last_update_submitted>
  <last_update_submitted_qc>October 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Professor Fernando Figueira Integral Medicine Institute</investigator_affiliation>
    <investigator_full_name>Alex Sandro Rolland de Souza</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Vascular calcification</keyword>
  <keyword>Coronary calcification</keyword>
  <keyword>Peritoneal Dialysis</keyword>
  <keyword>Spironolactone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcinosis</mesh_term>
    <mesh_term>Vascular Calcification</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

